Effect of ESWT on the microcirculation of the lower extremity in rats with diabetic vasculopathy: An experimental animal study Authors: Jie Zhang, Baiwei Zhang, Chunjing He Published: 2026 ABSTRACT ObjectivesThis study aimed to investigate the effects of extracorporeal shock wave therapy (ESWT) on the microcirculation of lower extremity skeletal muscle in rats with diabetic vasculopathy (DV) and to elucidate the potential underlying mechanism.Materials and methodsThe experimental animal study was conducted between August 2023 and February 2024. Forty healthy adult male Sprague-Dawley rats (mean weight: 226 ± 21 g; range, 205 to 247 g) were randomly assigned to five groups (n=8 per group): Control group (Group A), DV group (Group B), DV + ESWT group (Group C), DV + LY2157299 group (Group D), and DV + ESWT + LY2157299 group (Group E). The blood flow velocity and femoral artery diameter (FAD) on the right lower limb were measured using a high-resolution ultrasound system in all groups. Protein and messenger ribonucleic acid (mRNA) expression of phosphoinositide 3-kinase (PI3K), serine/threonine-protein kinase (AKT), and transforming growth factor-β1 (TGF-β1) in the femoral artery were analyzed using Western blotting and real-time polymerase chain reaction. The expression of CD31 in the gastrocnemius was measured using immunofluorescence.ResultsProtein expression of PI3K, AKT, and TGF-β1 was significantly lower in Groups C, D, and E than in Group B (p < 0.001, p < 0.001, and p < 0.001, respectively). The mRNA expression of AKT and TGF-β1 in Groups C, D, and E was significantly lower than that in Group B (p < 0.001, p < 0.001, and p < 0.001, respectively). The expression of CD31 in the gastrocnemius, FAD, and blood flow was significantly higher in Groups C, D, and E than in Group B (p < 0.05), with the highest expression in Group E compared with Groups C and D (p < 0.05).ConclusionExtracorporeal shock wave therapy can downregulate TGF-β1 expression, inhibit the PI3K/AKT pathway, increase gastrocnemius CD31 expression and lower limb blood flow, and improve blood microcirculation of lower limb skeletal muscle. Diabetic vascular disease is divided into macrovascular disease and microvascular disease, which are the main causes of disability and death and seriously affect the quality of life of patients with diabetes.[1, 2] Microangiopathy is one of the most common chronic complications in patients with diabetes. Recent studies have demonstrated that multiple metabolic disorders in the state of hyperglycemia can aggravate vascular endothelial dysfunction, which is also the initial factor in the occurrence and development of diabetes mellitus and its vascular complications. Moreover, studies have found that long-term hyperglycemia can lead to changes in the microvascular morphology and function, such as swelling and hyperplasia of microvascular endothelial cells, an increase in vascular permeability, vasodilation dysfunction, and abnormal hemorheology, thereby leading to blood circulation disorders, which is crucial in the pathogenesis of diabetic vasculopathy (DV).[3, 4] Studies have found that skeletal muscle with the most abundant blood flow is an important insulin receptor and one of the main target organs of diabetes. In addition, vascular endothelial dysfunction caused by various factors can negatively impact the microvascular insulin response, resulting in microvascular insulin resistance and reduced glucose uptake by skeletal muscle in pre-diabetes. Skeletal muscle hypoperfusion can easily cause glucose metabolism disorders. Vascular basement membrane thickening, non-enzymatic glycosylation of proteins, and a decrease in the number of new vessels are essential in the pathogenesis of diabetic microangiopathy in skeletal muscle.[5, 6] Therefore, improving the microcirculation of skeletal muscle is one of the keys to preventing and treating lower extremity vascular disease. Currently, the main treatment methods for lower extremity vascular disease include Western medicine, traditional Chinese medicine, intravascular interventional therapy, conventional surgery, and angiogenesis therapy; however, the effect is not satisfactory.[7, 8, 9] Therefore, the search for non-invasive, effective, and safe treatment is currently a hot research topic. Extracorporeal shock wave therapy (ESWT) can stimulate biological effects in vivo through mechanical conduction and may be used to treat various diseases other than non-urinary calculi.[10] This therapy has been shown to restore blood perfusion and improve microcirculation after acting on ischemic tissues and organs. It can also relieve patients’ pain by inhibiting inflammatory cells, oxidative stress response, and cell apoptosis.[11] Our previous study demonstrated that ESWT can not only inhibit inflammatory cell activation and oxidative stress response but also alleviate related symptoms of vascular disease by improving microcirculation.[12] However, the specific mechanism by which ESWT improves DV remains elusive. Hence, the present study established a rat model of DV to explore whether ESWT can improve skeletal muscle microcirculation of lower limbs and evaluate the potential underlying mechanism, which may assist in clinical treatment in the future. MaterialS AND METHODS The experimental study was conducted at Guizhou Provincial People’s Hospital, Department of of Pain, with 40 healthy adult specific pathogen-free male Sprague-Dawley rats (mean weight: 226 ± 21 g; range, 205 to 247 g) housed under controlled conditions (45 to 55% humidity, 21 to 23°C temperature, 12-h light-dark cycle) between August 2023 and February 2024. Before the study, all animals were monitored twice daily for behavioral health, food intake, and signs of distress. Animals had unlimited access to food and water. The experimental protocol was approved by the Ethics Committee of Guizhou Provincial People’s Hospital (Date: 20.08.2023, No. 2023-015) and adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 80-23). In this study, rats were included if they met the following criteria on day 7 after STZ induction: fasting blood glucose > 16.7 mmol/L, and no obvious signs of infection, lethargy, or paralysis. Animals were excluded if they showed fasting blood glucose < 16.7 mmol/L, died within 72 h after STZ injection, or died from any cause during the 4 week observation period. Excluded animals were immediately replaced with rats from the same batch and of the same age to maintain a final sample size of n = 8 per group. The rats were purchased from the Experimental Center of the Third Military Medical University (animal use license No. SCXK (Chongqing) 2012-0005). Regarding the determination of sample size, we comprehensively reviewed literature from previous similar studies and conducted a post hoc power analysis using G*Power software.[13, 14] We used the G*Power version 3.1 software (Heinrich Heine University Düsseldorf, Düsseldorf, Germany), selected ANOVA, input the effect size f, α = 0.05, the total sample size (40), and the number of groups (5) to conduct post hoc power analysis. Post hoc power analysis was performed on the key one-way ANOVA of blood flow velocity (BFV), femoral artery diameter (FAD), phosphoinositide 3-kinase (PI3K), serine/threonine-protein kinase (AKT), transforming growth factor-beta 1 (TGF-β1), and CD31. The analysis results indicated that the achieved power is 100% (α = 0.05), exceeding the conventional threshold by 80%. This confirmed that our sample size (n = 8 per group) was sufficient to detect the statistically significant differences observed in our study. So, animals were divided into five groups (n = 8 per group): Group A (control group), Group B (DV group), Group C (DV + ESWT group), Group D (DV + LY2157299 group), and Group E (DV + ESWT + LY2157299 group). Efforts to minimize animal suffering included using the statistically minimal sample size, employing sodium pentobarbital (Sigma Aldrich St. Louis, MO, USA) anesthesia for euthanasia, and implementing a humane endpoint protocol requiring prompt euthanasia upon predefined adverse event criteria. The observation period concluded after all treatments and ultrasound assessments were completed. Model establishment The combined model employed in this study was selected to replicate the pathological features of DV observed in humans. Streptozotocin is a well-established and widely utilized diabetogenic agent that selectively destroys pancreatic β-cells, inducing a state of chronic hyperglycemia analogous to type 1 diabetes mellitus.[15] For this reason, to establish the diabetic rat, rats in Groups B, C, D, and E were intraperitoneally injected with streptozotocin 60 mg/kg (Sigma Aldrich, St. Louis, MO, USA), and the rats in Group A were intraperitoneally injected with the same dose of normal saline. Blood glucose concentration of the caudal vein in each group was measured while fasting (after a 12-h fasting period) and seven days after fasting (after a 12-h fasting period). Rats with a caudal vein blood glucose concentration of > 16.7 mmol/L after injection for seven days were regarded as diabetic rats. Rats in Groups B, C, D, and E all met these requirements. To specifically model DV, we adopted a protocol involving low-dose warfarin (Sigma Aldrich St. Louis, MO, USA) administration combined with vitamin K (Kappa Bioscience AS, Oslo, Norway)supplementation. This combination has been demonstrated to reliably induce vascular pathology.[16] Therefore, rats in Groups B, C, D, and E received warfarin (20 mg/kg/day orally) and vitamin K (15 mg/kg/day subcutaneously) four weeks after diabetic modeling, and the doses were adjusted according to body weight every two days for three weeks.[17] ESWT and caudal vein administration After successful model establishment, rats in Groups C and D were injected with TGF-β receptor I inhibitor (LY2157299, Absin Bioscience. Inc, Shanghai, China) (1.5 mg/kg) through the caudal vein. Extracorporeal shock wave therapy (Swiss DolorClast, EMS, Nyon, Switzerland) was performed for lower limb vessels and skeletal muscle of rats in Groups C and E, and the parameters of shock wave therapy were 10 Hz, 1.0 bar, and 2000 waves per treatment, which were similar to previous study.[18, 19] Before treatment, the skin was prepared and disinfected. Femoral artery diameter and blood flow velocity After four weeks (T4), rats in Groups A, B, C, D, and E were intraperitoneally injected with 1% pentobarbital sodium (40 mg/kg), respectively, for anesthesia. After the skin was prepared and disinfected, arterial diameter and blood flow changes were measured using a high-resolution ultrasound system (EPIQ 5, Philips Healthcare, Hamburg, Germany) under constant scanning depth and gain conditions. After treatment, rats were intraperitoneally injected with 1% pentobarbital sodium (40 mg/kg), respectively, for anesthesia, and the lower extremity blood vessels and skeletal muscles were reserved for further studies. Western blotting The radioimmunoprecipitation assay lysate (Biosharp Life Science, Beijing, China) was mixed with phenylmethylsulfonyl fluoride at a volume ratio of 100:1. Lysed tissue samples were centrifuged at 12000 rpm, 4°C for 15 min. The protein concentration of the sample was measured using the BCA protein concentration assay kit (Beyotime, Shanghai, China). After electrophoresis with sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the separated proteins were transferred onto the polyvinylidene difluoridemembranes for 1.5 h, blocked with skimmed milk for 2 h. Membranes were incubated with primary antibodies against PI3K, AKT, and TGF-β1 (Abcam, Cambridge, MA, USA) at 4°C overnight, followed by incubation with a horseradish peroxidase-conjugated secondary antibody (Abcam, Cambridge, MA, USA) at room temperature for 1 h (dilution 1:1000). The ChemiDoc XRS + image system (Bio-Rad, China) with Image Lab software was used for visualization, and β-actin was used as an internal reference to analyze the protein level. The gray values of the band were analyzed using the ImageJ software (National Institutes of Health, Bethesda, MD, USA). Real-time polymerase chain reaction The femoral artery vessels of the lower limbs in all groups were collected, and total ribonucleic acid (RNA) was extracted using TRIzol reagent (Absin Bioscience. Inc, Shanghai, China) according to the manufacturer’s instructions. Briefly, 1 mL of TRIzol and 200 μL of chloroform were added subsequently to the sample, followed by centrifugation at 13000 rpm. The supernatant was transferred to a new centrifuge tube, precipitated in isopropyl alcohol, centrifuged at 13000 rpm, and washed with 75% ethanol. The optical density ratio at 260/280 nm was measured using an ultraviolet spectrophotometer (Thermo Scientific, Waltham, MA, USA) after a 50-fold dilution series of the RNA (2 μL). The total RNA was then reverse-transcribed into complementary deoxyribonucleic acid (cDNA) using a cDNA synthesis kit (Promega, Southampton, UK). The real-time polymerase chain reaction (RT-PCR) was performed using a reverse transcription kit (Promega, Southampton, UK) following the manufacturer’s protocol. The RT-PCR reaction conditions were as follows: 40 cycles of 95°C for 15 s, 55°C for 15 s, and 72°C for 15 s. All experiments were repeated three times. Relative quantification of gene expression was performed using the comparative Ct method (2-rrCT method). The primer sequences are listed in supplementary Table S1. Immunofluorescence The gastrocnemius muscles of rats were taken and fixed with 4% paraformaldehyde, and then wax blocks were prepared by dehydration and paraffin embedding. The wax block specimens (5 μm thick) were dried on polylysine-treated anti-detachment slides. The slices were dewaxed in xylene and hydrated with distilled water after a graded series of alcohol (100%, 95%, 80%, 70%). Slices were washed twice in phosphate-buffered saline (PBS) for 5 min. Samples were incubated with 3% hydrogen peroxide for 10 min to eliminate endogenous peroxidase activity and then washed twice with PBS for 3 min. Then, 0.01 M citrate buffer (pH 6.0) was added to the sample and boiled for 8 min. After cooling at room temperature, samples were washed twice with PBS for 5 min. Normal goat serum working solution was added to the sample and incubated at room temperature for 15 min. After the serum was poured out, samples were incubated with a primary antibody against rabbit pAb (Servicebio, Wuhan, Hubei, China) at 4°C overnight, followed by incubation with goat anti-rabbit IgG (Abcam, Cambridge, MA, USA) at room temperature for 20 min. Samples were washed three times with PBS for 3 min, stained with 4¢,6-diamidino-2-phenylindole (DAPI, Abcam, Cambridge, MA, USA) for 3 min, and then mounted with a cover glass and an antifade reagent. Statistical analysis Statistical analysis was performed using the IBM SPSS version 20.0 software (IBM Corp., Armonk, NY, USA). Normality was confirmed via Shapiro-Wilk tests (all p > 0.05), and homogeneity of variances was verified using Levene's test (all p > 0.05). Pairwise comparisons were conducted with Tukey's HSD test. The measurement data were expressed as mean ± standard deviation (SD). One-way ANOVA was used for comparison between groups, and Fisher’s least significant difference method was used for pair-to-group comparison. A p-value < 0.05 was considered statistically significant. RESULTS At T4, compared with Group A, the FAD decreased significantly in Groups B to E (p < 0.001, p < 0.001, p < 0.001, and p = 0.025, respectively), while compared with Group B, the FAD increased dramatically in Groups C to E (p = 0.003, p = 0.006, and p < 0.001, respectively). Compared with Group C, the FAD increased in Group E (p = 0.025). Moreover, the FAD increased significantly in Group E compared with Group D (p = 0.012), as shown in Figures 1, 2, and Table 1. At T4, the femoral flow velocity decreased significantly in Groups B, C, D, and E (p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively) compared with Group A and increased dramatically in Groups C, D, and E (p < 0.001, p < 0.001, and p < 0.001, respectively) compared with Group B. Compared with Group C, the femoral flow velocity increased in Group E (p < 0.001). Moreover, the femoral flow velocity increased significantly in Group E compared with Group D (p < 0.001) (Figures 1, 2; Table 1). At T4, the expression levels of PI3K, AKT, and TGF-β1 were significantly increased in all groups, except for Group A (p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively). Compared with Group B, expression levels of PI3K, AKT, and TGF-β1 were significantly reduced in Groups C, D, and E (p < 0.001, p < 0.001, and p < 0.001 respectively). Compared with Group C, the expression levels of PI3K, AKT, and TGF-β1 in Group D increased (p < 0.001, p = 0.021, p < 0.001), and the PI3K protein in Group E decreased (p = 0.001), while no significant differences were observed in the expression levels of AKT (p = 0.995) and TGF-β1 (p = 0.052) in Group E. Additionally, compared with Group D, the expression levels in Group E of PI3K, AKT, and TGF-β1 (p < 0.001, p = 0.021, and p < 0.001, respectively) were significantly decreased, as shown in Figure 3 and Table 2. At T4, compared with Group B, messenger RNA (mRNA) expression levels in Groups A, C, D, and E (p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively) of AKT and TGF-β1 were significantly decreased. The expression level of TGF-β1 mRNA in Group E was significantly lower than that in Groups C and D (p < 0.001, p < 0.001). Additionally, the relative expression levels of AKT in Groups C and E were significantly reduced compared with Group D (p < 0.001, p < 0.001). Furthermore, there was no significant difference in the relative expression of AKT mRNA between Group C and E (p = 0.553), as shown in Figure 4 and Table 3. At T4, compared with Group A, the expression of CD31 (red) was significantly reduced in Groups B, C, D, and E (p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively). Meanwhile, the expression of CD31 was significantly increased in Groups C, D, and E compared with Group B (p < 0.001, p < 0.001, and p < 0.001, respectively). Moreover, the expression of CD31 was significantly increased in Group E compared with Groups C and D (p = 0.001, p < 0.001), as shown in Figure 5 and Table 4. DISCUSSION Extracorporeal shock wave therapy can improve circulation and make the body produce nitric oxide by concentrating energy release on ischemic organs and tissues, as well as react with adenosine cyclase of intracellular hemoglobin to dilate small blood vessels and reduce inflammation, thereby alleviating vascular lesions. In addition, it was previously reported that ESWT can improve myocardial perfusion and increase capillary density in patients with coronary heart disease.[6, 20] Using a diabetes rat model, Long et al.[18] also found that ESWT may alleviate angiopathy by upregulating vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) to increase angiogenesis and enhance vasoconstriction. Furthermore, our prior research indicated that the extracorporeal shock wave can reduce the expression of vascular adhesion molecules and improve hemodynamics to treat diabetes-induced vascular lesions with relative safety and fewer side effects.[19] Our previous studies also revealed that ESWT can improve the symptoms of DV in rats.[18, 19] The present study demonstrated that the expression of an endothelial cell marker, CD31, in the skeletal muscle of the vascular lesion group was significantly decreased and then increased after ESWT or LY2157299 treatment, and the increase in CD31 was more significant after the combination of both. In addition, vascular ultrasound in the current study showed that the femoral artery blood flow and BFV of DV rats were slowed down, and the FAD, BFV, and blood flow of DV rats were significantly better after ESWT or LY2157299 treatment than without treatment. Diabetic vasculopathy reduced lower extremity BFV and blood flow and impaired the blood microcirculation of lower limb skeletal muscle. However, ESWT or LY2157299 treatment effectively improved the FAD, BFV, and blood flow, thereby improving the microcirculation of skeletal muscle and contributing to the regeneration of gastrocnemius muscle microvessels. In addition, the lower extremity blood flow and BFV were improved more significantly after combined treatment. The TGF-β signaling pathway plays an extremely important role in regulating cell proliferation, differentiation, invasion, inflammation, and other life activities from embryonic development to mature tissues and can be divided into classical and non-classical pathways. Among them, the non-classical TGF-β pathway can be activated by activating PI3K/AKT, mitogen-activated protein kinase, nuclear factor kappa B, and other signaling pathways.[21, 22] Transforming growth factor-β1 is a homodimeric polypeptide involved in cell proliferation and differentiation and the regulation of extracellular matrix metabolism. It also activates the signaling pathway after binding to the TGF-β1 receptor.[23] The TGF-β receptor I inhibitor (Galunisertib), also known as LY2157299, competitively binds TβRI to TGF-β1, further affecting the activation of the classical TGF-β signaling pathway.[24] Research has revealed that TGF-β can damage vascular endothelium and accelerate the formation of atherosclerotic plaque in type 2 diabetes patients with inflammatory factors, and further increase major vascular diseases.[25] Transforming growth factor-β can also promote the formation of atherosclerosis by mediating the production of inflammatory factors in various ways, thereby destroying the function of vascular endothelium. In addition, it has been shown that TGF-β1 can reduce the generation of matrix-degrading enzymes during extracellular matrix deposition and as an important part of vascular endothelial injury.[26] Collectively, these studies suggest that in the occurrence and development of diabetes, TGF-β1 may mediate the release of inflammatory factors through the activation of the TGF-β signaling pathway, destroy vascular endothelial cells, and further lead to pathological changes in micro- and macro-vessels. The PI3K/AKT signaling pathway promotes cell growth, proliferation, and metabolism and inhibits cell apoptosis.[27] Studies on the association between the PI3K/AKT signaling pathway and diabetes mellitus, liver fibrosis, etc., have attracted considerable attention in recent years.[28, 29, 30] Gao[31] demonstrated that Shenqi compound formula inhibited the expression of PI3K/AKT/eNOS, thereby reducing the expression of VEGF, inhibiting the apoptosis of endothelial cells, and preventing the formation of atheromatous plaque and pathological neovasculature. Xiao et al.[32] found that sustained hyperglycemia stimulated the activation of the PI3K/AKT pathway, thus promoting the expression of hypoxia-inducible factor-1 alpha, VEGF, and other downstream genes, further causing the abnormal proliferation and migration of vascular endothelial cells and promoting the occurrence and development of DV. Zhang et al.[33] demonstrated that activated hepatic stellate cells can promote the secretion of TGF-β1 and directly or indirectly activate the PI3K/AKT signaling pathway, playing an important regulatory role in angiogenesis and other processes. Together, all the above studies indicate that the TGF-β1/PI3K/AKT signaling pathway plays a pivotal role in the occurrence and development of DV. Moreover, the present study demonstrated that TGF-β1, PI3K, and AKT expression levels were significantly elevated in the femoral artery of DV rats, suggesting that the high-glucose environment may induce the activation of the TGF-β1 signaling pathway in the femoral artery of diabetic rats and aggravate its damage. However, TGF-β1, PI3K, and AKT expression levels were significantly reduced after ESWT or LY2157299 treatment. In addition, expression levels of TGF-β1, PI3K, and AKT were significantly reduced after combined treatment (ESWT + LY2157299). Thus, ESWT combined with LY2157299 may attenuate the activation of the TGF-β1 signaling pathway, inhibit the PI3K/AKT pathway, improve microcirculation in the lower limbs of diabetic rats, and promote the repair of lower limb microvascular injury. This study has several limitations. First, although the rat model provides critical insights into the mechanisms of diabetic vascular complications, the differences in vascular anatomy, metabolic regulation, and disease progression patterns between rodents and humans may restrict the clinical translatability of the findings. Second, the observation period was limited to four weeks post-intervention, lacking rigorous evaluation of the long-term efficacy and safety of ESWT and LY2157299. Last, future studies should involve large-scale, long-term multi-species investigations combined with preclinical and clinical data to further validate the stability and human applicability of this combined therapeutic strategy. In conclusion, lower extremity BFV and blood flow were reduced, and skeletal muscle microcirculation was impaired in DV rats. However, ESWT or LY2157299 treatment downregulated TGF-β1, inhibited the PI3K/AKT pathway, improved BFV and blood flow, and enhanced skeletal muscle microcirculation in lower limbs in rats with DV, to promote the regeneration of skeletal muscle microvascular. The blood flow and blood velocity of the lower extremity in rats were improved more significantly, and the microcirculation of the lower skeletal muscle was further improved after combined treatment.